Y-mAbs Therapeutics (YMAB) News Today $4.41 +0.30 (+7.30%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$4.41 0.00 (0.00%) As of 05/2/2025 05:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Caligan Partners LP Has $13.84 Million Stock Position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)Caligan Partners LP grew its stake in shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) by 47.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,767,982 shares of the company's stocMay 3 at 7:44 AM | marketbeat.comRenaissance Technologies LLC Raises Position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)Renaissance Technologies LLC grew its stake in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) by 371.7% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 131,600 shares of the company's stock after purchasing an additionMay 3 at 3:38 AM | marketbeat.comY-mAbs Therapeutics (YMAB) Projected to Post Earnings on TuesdayY-mAbs Therapeutics (NASDAQ:YMAB) will be releasing its Q1 2025 earnings before the market opens on Tuesday, May 6. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-6-y-mabs-therapeutics-inc-stock/)May 1 at 9:32 AM | marketbeat.comJPMorgan Chase & Co. Raises Stock Holdings in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)JPMorgan Chase & Co. boosted its holdings in shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) by 221.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 97,660 shares of the company's stoApril 30 at 3:04 AM | marketbeat.comBoothbay Fund Management LLC Buys 136,264 Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)Boothbay Fund Management LLC grew its stake in shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) by 24.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 693,693 shares of the company's stock after purchasing an additionaApril 29, 2025 | marketbeat.comY-mAbs Therapeutics announces presentation of PK data of CD38-SADAApril 28, 2025 | markets.businessinsider.comY-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) latest 13% decline adds to one-year losses, institutional investors may consider drastic measuresApril 27, 2025 | finance.yahoo.comY-mAbs Presents Translational Pharmacokinetics of CD38-SADA from Pretargeted RIT Platform at 2025 American Association for Cancer Research (AACR) Annual MeetingApril 27, 2025 | globenewswire.comBrookline Capital Management Weighs in on YMAB Q1 EarningsY-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) - Equities research analysts at Brookline Capital Management lowered their Q1 2025 earnings per share estimates for Y-mAbs Therapeutics in a research note issued to investors on Tuesday, April 22nd. Brookline Capital Management analyst K. DollApril 27, 2025 | marketbeat.comY-mAbs announces first patient dosed in Phase 1 trial of CD38-SADA PRIT platformApril 26, 2025 | markets.businessinsider.comYMAB Q1 EPS Estimate Reduced by Brookline Capital ManagementApril 26, 2025 | americanbankingnews.comY-mAbs Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating CD38-SADA Pre-targeted Radioimmunotherapy in Relapsed/Refractory Non-Hodgkin LymphomaApril 25, 2025 | globenewswire.comY-mAbs Therapeutics (NASDAQ:YMAB) Downgraded to "Underperform" Rating by Bank of AmericaBank of America cut shares of Y-mAbs Therapeutics from a "neutral" rating to an "underperform" rating and set a $3.00 price objective for the company. in a research report on Tuesday.April 24, 2025 | marketbeat.comY-mAbs Therapeutics (NASDAQ:YMAB) Rating Lowered to "Underperform" at Bank of AmericaApril 24, 2025 | americanbankingnews.comY-mAbs Therapeutics downgraded to Underperform from Neutral at BofAApril 23, 2025 | markets.businessinsider.comY-mAbs downgraded to Underperform at BofA on tough near-term setupApril 23, 2025 | markets.businessinsider.comY-mAbs drops as Bank of America downgrades on headwinds to DanyelzaApril 23, 2025 | msn.comY-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Consensus Recommendation of "Moderate Buy" from AnalystsShares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the eleven analysts that are presently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one hasApril 21, 2025 | marketbeat.comY-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Short Interest UpdateY-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Get Free Report) was the target of a large decline in short interest during the month of March. As of March 31st, there was short interest totalling 3,660,000 shares, a decline of 17.6% from the March 15th total of 4,440,000 shares. Approximately 10.6% of the shares of the company are short sold. Based on an average trading volume of 426,500 shares, the days-to-cover ratio is presently 8.6 days.April 21, 2025 | marketbeat.comY-mAbs Therapeutics, Inc.April 16, 2025 | cnn.comY-mAbs Therapeutics: A Yawn From The Market Means OpportunityApril 11, 2025 | seekingalpha.comY-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Shares Bought by Pictet Asset Management Holding SAPictet Asset Management Holding SA grew its position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) by 9.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 756,297 shares of the company's stock aApril 5, 2025 | marketbeat.comY-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Given Average Rating of "Moderate Buy" by BrokeragesShares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Get Free Report) have received an average rating of "Moderate Buy" from the eleven research firms that are currently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, one has given a hold rating, seven havMarch 26, 2025 | marketbeat.comBreaking Down Y-mAbs Therapeutics: 5 Analysts Share Their ViewsMarch 23, 2025 | nasdaq.comHC Wainwright Cuts Y-mAbs Therapeutics (NASDAQ:YMAB) Price Target to $12.00HC Wainwright decreased their price objective on shares of Y-mAbs Therapeutics from $22.00 to $12.00 and set a "buy" rating for the company in a report on Friday.March 22, 2025 | marketbeat.comY-mAbs Therapeutics price target lowered to $12 from $22 at H.C. WainwrightMarch 21, 2025 | markets.businessinsider.com4YMAB : Breaking Down Y-mAbs Therapeutics: 5 Analysts Share Their ViewsMarch 21, 2025 | benzinga.comY-mAbs Therapeutics, Inc. (NASDAQ:YMAB) CEO Sells $20,368.40 in StockY-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Get Free Report) CEO Michael J. Rossi sold 3,917 shares of the firm's stock in a transaction dated Friday, March 7th. The stock was sold at an average price of $5.20, for a total value of $20,368.40. Following the completion of the transaction, the chief executive officer now directly owns 137,083 shares in the company, valued at $712,831.60. This trade represents a 2.78 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.March 12, 2025 | marketbeat.comY-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Insider Thomas Gad Sells 10,810 SharesY-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Get Free Report) insider Thomas Gad sold 10,810 shares of Y-mAbs Therapeutics stock in a transaction on Friday, March 7th. The stock was sold at an average price of $5.23, for a total transaction of $56,536.30. Following the completion of the transaction, the insider now directly owns 202,721 shares of the company's stock, valued at $1,060,230.83. The trade was a 5.06 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.March 12, 2025 | marketbeat.comY-mAbs Therapeutics, Inc. (NASDAQ:YMAB) CEO Michael J. Rossi Sells 3,917 SharesMarch 12, 2025 | insidertrades.comBearish: Analysts Just Cut Their Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Revenue and EPS estimatesMarch 9, 2025 | finance.yahoo.comYMAB FY2025 EPS Forecast Lowered by Cantor FitzgeraldY-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) - Research analysts at Cantor Fitzgerald dropped their FY2025 EPS estimates for Y-mAbs Therapeutics in a research note issued to investors on Wednesday, March 5th. Cantor Fitzgerald analyst L. Watsek now anticipates that the company will postMarch 8, 2025 | marketbeat.comQ1 EPS Estimate for Y-mAbs Therapeutics Boosted by AnalystY-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) - Equities researchers at Brookline Capital Management lifted their Q1 2025 earnings estimates for Y-mAbs Therapeutics in a note issued to investors on Tuesday, March 4th. Brookline Capital Management analyst K. Dolliver now anticipates that tMarch 8, 2025 | marketbeat.comWedbush Equities Analysts Lower Earnings Estimates for YMABY-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) - Analysts at Wedbush reduced their Q1 2025 earnings per share (EPS) estimates for shares of Y-mAbs Therapeutics in a research report issued to clients and investors on Tuesday, March 4th. Wedbush analyst D. Nierengarten now anticipates that tMarch 8, 2025 | marketbeat.comTruist Financial Cuts Y-mAbs Therapeutics (NASDAQ:YMAB) Price Target to $18.00Truist Financial dropped their price target on shares of Y-mAbs Therapeutics from $21.00 to $18.00 and set a "buy" rating on the stock in a research report on Wednesday.March 6, 2025 | marketbeat.comY-mAbs Therapeutics (NASDAQ:YMAB) Given New $12.00 Price Target at Bank of AmericaBank of America lowered their target price on shares of Y-mAbs Therapeutics from $14.00 to $12.00 and set a "neutral" rating for the company in a research note on Wednesday.March 6, 2025 | marketbeat.comY-mAbs Therapeutics (NASDAQ:YMAB) Given New $7.00 Price Target at Morgan StanleyMorgan Stanley reduced their price objective on Y-mAbs Therapeutics from $11.00 to $7.00 and set an "underweight" rating for the company in a research note on Wednesday.March 6, 2025 | marketbeat.comForecasting The Future: 4 Analyst Projections For Y-mAbs TherapeuticsMarch 5, 2025 | benzinga.comY-mAbs Therapeutics price target lowered to $12 from $14 at BofAMarch 5, 2025 | markets.businessinsider.comY-Mabs Therapeutics (YMAB) Gets a Buy from OppenheimerMarch 5, 2025 | markets.businessinsider.comY-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q4 2024 Earnings Call TranscriptMarch 5, 2025 | msn.comY-mAbs Therapeutics, Inc. (YMAB) Q4 2024 Earnings Call TranscriptMarch 4, 2025 | seekingalpha.comY-mAbs Therapeutics' (YMAB) "Outperform" Rating Reaffirmed at WedbushWedbush restated an "outperform" rating and issued a $23.00 price target on shares of Y-mAbs Therapeutics in a research note on Monday.March 4, 2025 | marketbeat.comY-mAbs Therapeutics, Inc.: Y-mAbs Reports Fourth Quarter 2024 Financial Results and Recent Corporate DevelopmentsMarch 4, 2025 | finanznachrichten.deY-mAbs Shares Fall After Outlook, 4Q Revenue MissMarch 4, 2025 | marketwatch.comY-mAbs Therapeutics reports Q4 EPS (15c), consensus (13c)March 4, 2025 | markets.businessinsider.comY-mAbs Therapeutics sees 2025 revenue $75M-$90M, consensus $105.76MMarch 4, 2025 | markets.businessinsider.comY-mAbs Therapeutics (NASDAQ:YMAB) shareholders have endured a 79% loss from investing in the stock five years agoMarch 4, 2025 | finance.yahoo.comY-mAbs Therapeutics (NASDAQ:YMAB) Announces Earnings Results, Misses Expectations By $0.02 EPSY-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) posted its earnings results on Tuesday. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.02). Y-mAbs Therapeutics had a negative net margin of 28.22% and a negative return on equity of 24.61%.March 4, 2025 | marketbeat.comY-mAbs Reports Fourth Quarter 2024 Financial Results and Recent Corporate DevelopmentsMarch 4, 2025 | globenewswire.com Get Y-mAbs Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for YMAB and its competitors with MarketBeat's FREE daily newsletter. Email Address YMAB Media Mentions By Week YMAB Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. YMAB News Sentiment▼0.510.58▲Average Medical News Sentiment YMAB News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. YMAB Articles This Week▼104▲YMAB Articles Average Week Get Y-mAbs Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for YMAB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies RCKT News Today QURE News Today XNCR News Today LENZ News Today PAHC News Today IMNM News Today PRAX News Today NUVB News Today EOLS News Today REPL News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:YMAB) was last updated on 5/3/2025 by MarketBeat.com Staff From Our PartnersThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThe collapse has already startedThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Y-mAbs Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Y-mAbs Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ymab Stock Free ymab Stock Alerts